Daae L N, Kierulf P, Brusletto B, Westheim A, Holme I, Syvertsen J O
Klinisk kjemisk avdeling, Ullevål sykehus, Oslo.
Tidsskr Nor Laegeforen. 1991 Apr 10;111(9):1102-5.
Hypertensive cigarette smokers run particularly high risk of coronary heart disease. Doxazosin, which has beneficial effects on haemodynamic factors and lipid metabolism, may be a suitable agent for treating these patients. The effects on blood pressure and metabolic parameters were investigated in a 16-week, open, parallel, comparative study comprising 64 heavy cigarette smokers and 69 non-smokers who received doxazosin after four weeks on placebo. Eight patients (three smokers and five non-smokers) dropped out due to adverse effects. Blood pressure was significantly reduced in both groups, but there was no change in heart rate. Doxazosin induced a decrease in the triglyceride, total cholesterol and LDL-cholesterol levels, and an increase in HDL-cholesterol concentration. Thus, doxazosin has favourable effects on atherogenic factors in smoking hypertensive patients. There was also a significant lowering of plasma fibrinogen levels and plasminogen activator inhibitor (PAI-1) concentration in non-smokers.
高血压吸烟者患冠心病的风险特别高。多沙唑嗪对血流动力学因素和脂质代谢有有益作用，可能是治疗这些患者的合适药物。在一项为期16周的开放、平行、对照研究中，对血压和代谢参数的影响进行了调查，该研究包括64名重度吸烟者和69名不吸烟者，他们在服用四周安慰剂后接受了多沙唑嗪治疗。8名患者（3名吸烟者和5名不吸烟者）因不良反应退出。两组血压均显著降低，但心率无变化。多沙唑嗪可降低甘油三酯、总胆固醇和低密度脂蛋白胆固醇水平，并提高高密度脂蛋白胆固醇浓度。因此，多沙唑嗪对吸烟高血压患者的致动脉粥样硬化因素有有利影响。不吸烟者的血浆纤维蛋白原水平和纤溶酶原激活物抑制剂（PAI-1）浓度也显著降低。
